SPY411.45-1.41 -0.34%
DIA337.53+0.74 0.22%
IXIC13,857.84-138.26 -0.99%

BRIEF-Merck Receives Priority Review From FDA For New Drug Application For Hif-2Α Inhibitor Belzutifan (Mk-6482)

· 03/16/2021 06:46
BRIEF-Merck Receives Priority Review From FDA For New Drug Application For Hif-2Α Inhibitor Belzutifan (Mk-6482)

- Merck & Co Inc MRK.N:

  • MERCK RECEIVES PRIORITY REVIEW FROM FDA FOR NEW DRUG APPLICATION FOR HIF-2Α INHIBITOR BELZUTIFAN (MK-6482)

  • MERCK RECEIVES PRIORITY REVIEW FROM FDA FOR NEW DRUG APPLICATION FOR HIF-2Α INHIBITOR BELZUTIFAN (MK-6482)

  • MERCK & CO INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION, DATE OF SEPTEMBER 15, 2021

Source text for Eikon: ID:nBwbBRLLta

Further company coverage: MRK.N


((Reuters.Briefs@thomsonreuters.com;))